SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to ...
Please provide your email address to receive an email when new articles are posted on . The 7-year intracranial progression free-survival among patients treated with combination therapy was 42%.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback